Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $5.63 million.

For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.

Earnings